Related Experiment Video
Updated: Aug 8, 2026
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Medulloblastomas: new directions in risk stratification
Chitra Sarkar1, Prabal Deb, Mehar Chand Sharma
1Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. drchitrasarkar@yahoo.com
Abstract:
Medulloblastomas (MBs) are the most common malignant brain tumors in children. Current therapeutic approaches combine surgery, radiotherapy, and chemotherapy. Although, there has been significant improvement in long-term survival rates, the tumor remains incurable in about a third of patients while cognitive deficits and other sequelae of therapy are common among long-term survivors. Hence a major challenge remains to differentiate high-from low-risk patients and to tailor therapy based on the degree of biological aggressiveness. A clinical risk-stratification system has been widely used in MBs based on age, extent of resection and the Chang staging system. However, recent reports indicate that these clinical variables are inadequate methods of defining disease risk. This has prompted search for new markers for MB stratification. Recent studies indicate that the classification of MBs according to profiles of histopathology and molecular abnormalities possibly help better risk-stratification of patients, thereby rationalizing approaches to therapy, increasing cure rate, reducing long-term side effects and developing novel therapeutic strategies. The most accurate outcome prediction till date has been obtained through microarray gene expression profiling. In this article, the current histopathological classification and the recent advances in molecular genetics of MBs are reviewed. Global efforts to translate this knowledge of disease biology into clinical practice especially as outcome predictors are highlighted.
Insights
Medulloblastomas (MBs), common pediatric brain tumors, require better risk stratification beyond current clinical methods. Molecular profiling, especially gene expression, offers improved outcome prediction for tailored treatments and reduced side effects.
Area of Science:
- Pediatric neuro-oncology
- Cancer genetics
- Molecular diagnostics
Background:
- Medulloblastomas are the most frequent malignant pediatric brain tumors.
- Current treatments (surgery, radiotherapy, chemotherapy) improve survival but have limitations, with a significant portion of patients remaining incurable and survivors facing long-term side effects.
- Existing clinical risk-stratification methods for medulloblastomas are insufficient for precise patient management.
Purpose of the Study:
- To review current histopathological classifications of medulloblastomas.
- To explore recent advances in the molecular genetics of medulloblastomas.
- To highlight the translation of molecular insights into clinical practice for improved outcome prediction.
Main Methods:
- Review of current histopathological classifications.
- Analysis of recent molecular genetics research in medulloblastomas.
- Examination of microarray gene expression profiling for outcome prediction.
Main Results:
- Histopathological and molecular profiling offer superior risk-stratification compared to traditional clinical variables.
- Microarray gene expression profiling has demonstrated the highest accuracy in predicting medulloblastoma outcomes to date.
- Molecular insights are crucial for developing novel therapeutic strategies and refining treatment approaches.
Conclusions:
- Accurate risk stratification of medulloblastomas is essential for optimizing therapy and improving patient outcomes.
- Molecular genetics and gene expression profiling represent promising tools for enhancing risk assessment and guiding clinical decisions.
- Translating molecular findings into clinical practice holds the key to increasing cure rates and minimizing treatment-related toxicities in pediatric medulloblastoma patients.
